ACE 2016
Alternative Names: ACE-2016Latest Information Update: 06 Feb 2024
At a glance
- Originator Acepodia
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Feb 2024 US FDA approves IND application for ACE 2016 in Solid tumours
- 04 Feb 2024 Acepodia plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease) in USA (parenteral) in second half of 2024
- 14 Apr 2023 Pharmacodynamics data from a Preclinical trial in Solid tumours presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)